5 must-know fall application deadlines for Houston innovators

apply now

Lilie's 2026 Rice Innovation Fellows. Photo via LinkedIn

Editor's note: As fall reaches full swing, Houston's innovation scene is calling on the latest batch of founders and startups looking to make a difference. A number of accelerators have opened applications. Read below to see which might be a good fit for you or your venture. And take careful note of the deadlines. Please note: this article may be updated to include additional information and programs.

Did we miss an accelerator or competition accepting applications? Email innoeditor@innovationmap.com for editorial consideration.

Texas Life Science Forum

Deadline: Oct. 2

Details: Ventures can apply to present at the 15th annual Texas Life Science Forum, hosted by BioHouston and Rice Alliance. Participants will meet during office hours with venture capitalists, tech scouts, corporate venture groups and angel investors, and present their pitches in a public forum. Pitches take place on Nov. 10 and office hours are held Nov. 11. Find more information here.

Greentown Lab's Go Make 2027: Advanced Carbon Materials with ExxonMobil

Deadline: Oct. 9

Details: Greentown Labs is seeking applications from startups developing novel carbon-based technologies for its latest Go Make cohort in conjunction with ExxonMobil. The structured accelerator is designed to facilitate validation activities and explore potential long-term collaborations with Exxon, according to Greentown. Founders will have the opportunity to engage directly with industry leaders to test, validate and scale their carbon technologies in real commercial contexts. The program tentatively starts on Jan. 20, 2027 and concludes June 16, 2027. Find more information here.

Activate's U.S. Fellowship Cohort 2027

Deadline: Oct. 30

Details: Activate supports scientists at "the outset of their entrepreneurial journey." It partners with U.S.-based funders and research institutions to support its fellows in developing high-impact technology. Its fellows receive a living stipend, research and development funding, connections from Activate's robust network of mentors and access to a curriculum specific to the program for two years. Applicants must have a bachelor’s degree and 4-plus years of post-baccalaureate scientific research, engineering or technology development experience. Their work must be based in the physical or biological sciences or related engineering disciplines. Find more information here.

Rice Innovation Fellows

Deadline: Oct. 30

Details: The Liu Idea Lab for Innovation and Entrepreneurship (Lilie)'s Rice Innovation Fellows program supports Rice Ph.D. students and postdocs in turning their research into real-world ventures. Participants receive $10,000 in translational research funding, co-working space and personalized mentorship. Candidates from all Rice engineering and science-related disciplines are encouraged to apply. Find more information here.

The TMC's Accelerator for Cancer Therapeutics

Deadline: Oct. 30

Details: Texas-based ventures and researchers developing a cancer therapeutics project can apply to this accelerator funded by the Cancer Prevention and Research Institute of Texas. The nine-month program runs February-September 2027 and focuses on market research, FDA regulations, intellectual property, licensing, finance, fundraising, legal and other critical areas for cancer-related ventures. Participants will complete the program with at least one grant submission and have the option to pitch to investors, corporate partners, media and other influential guests. Find more information here.

From Your Site Articles
CrossBridge Bio co-founder and CEO Michael Torres. Photo via LinkedIn

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
The Cancer Prevention and Research Institute of Texas has awarded its latest round of grants. Photo via tmc.edu

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.
Innovators in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies have joined TMC's Accelerator for Cancer Therapeutics. Photo courtesy TMC.

TMC names 2025 cohort of cancer treatment innovators

ready to grow

Texas Medical Center Innovation has named more than 50 health care innovators to the fifth cohort of its Accelerator for Cancer Therapeutics (ACT).

The group specializes in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies, according to a statement from TMC.

During the nine-month ACT program, participants will enjoy access to a network of mentors, grant-writing support, chemistry resources, and the entrepreneur-in-residence program. The program is designed to equip participants with the ability to secure investments, develop partnerships, and advance the commercialization of cancer therapeutics in Texas.

“With over 35 million new cancer cases predicted by 2050, the urgency to develop safer, more effective, and personalized treatments cannot be overstated,” Tom Luby, chief innovation officer at Texas Medical Center, said in a news release.

Members of the new cohort are:

  • Alexandre Reuben, Kunal Rai, Dr. Cassian Yee, Dr. Wantong Yao, Dr. Haoqiang Ying, Xiling Shen, and Zhao Chen, all of the University of Texas MD Anderson Cancer Center
  • Dr. Andre Catic and Dr. Martin M. Matzuk, both of the Baylor College of Medicine
  • Cynthia Hu and Zhiqiang An, both of UTHealth Houston
  • Christopher Powala, Aaron Sato, and Mark de Souza, all of ARespo Biopharma
  • Daniel Romo, Dr. Susan Bates, and Ken Hull, all of Baylor University
  • Eugene Sa & Minseok Kim, both of CTCELLS
  • Gomika Udugamasooriya and Nathaniel Dawkins, both of the University of Houston
  • Dr. Hector Alila of Remunity Therapeutics
  • Iosif Gershteyn and Victor Goldmacher, both of ImmuVia
  • João Seixas, Pedro Cal, and Gonçalo Bernardes, all of TargTex
  • Ken Hsu and Yelena Wetherill, both of the University of Texas at Austin
  • Luis Martin and Dr. Alberto Ocaña, both of C-Therapeutics
  • Dr. Lynda Chin, Dr. Keith Flaherty, Dr. Padmanee Sharma, James Allison, and Ronan O’Hagan, all of Project Crest/Apricity Health
  • Michael Coleman and Shaker Reddy, both of Metaclipse Therapeutics
  • Robert Skiff and Norman Packard, both of 3582.ai
  • Rolf Brekken, Uttam Tambar, Ping Mu, Su Deng, Melanie Rodriguez, and Alexander Busse, all of UT Southwestern Medical Center
  • Ryan Swoboda and Maria Teresa Sabrina Bertilaccio, both of NAVAN Technologies
  • Shu-Hsia Chen and Ping-Ying Pan, both of Houston Methodist
  • Thomas Kim, Philipp Mews, and Eyal Gottlieb, all of ReEngage Therapeutics
The ACT launched in 2021 and has had 77 researchers and companies participate. The group has collectively secured more than $202 million in funding from the NIH, CPRIT and venture capital, according to TMC.
CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort.

TMC names 2024 cohort of cancer treatment innovators

ready to grow

For the fourth year, Texas Medical Center Innovation has named its annual cohort of Texas health tech innovators working on promising cancer therapeutics.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort last week, and the 23 Texas researchers and companies selected will undergo a nine-month program that will provide them with mentorship and programming, as well as open doors to potential investors and strategic partners.

“The ACT program provides a bridge to commercialization in Texas by surrounding innovators with strategic mentorship, milestone development, and a network of resources to move their projects forward,” Emily Reiser, associate director of TMC Innovation, says in a news release. "We are excited to welcome this year's cohort and to continue enabling participants to advance their solutions to treat cancer."

The program has accelerated 76 researchers and companies to date, many of which — like March Biosciences and Mongoose Bio — have gone on to secure $130 million in funding from venture capitalists and grant funding.

“Our program has cultivated a dynamic ecosystem where partners, researchers, and inventors, who have been part of the journey since its inception and received various forms of funding, continue to propel their life-saving products and technologies forward," Ahmed AlRawi, program manager of ACT, says in the release. "Our 2024 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. Additionally, we are particularly proud that the cohort includes a blend of new and recurring organizations that have leveraged this opportunity in the past to extend their work and continue the momentum to build off the successes of our previous years.”

The 2024 participants are:

  • Alexandre Reuben of UT-MD Anderson Cancer Center
  • Betty Kim & Jiang Wen of UT-MD Anderson Cancer Center
  • Bin He of Houston Methodist
  • Daniel Kiss & John Cooke of PeakRNA at Houston Methodist
  • Hongjun Liang of Texas Tech-Lubbock
  • Jacob Goell & Isaac Hilton of Mercator Biosciences at Rice University
  • Jay Hartenbach & Matthew Halpert of Diakonos Oncology Corp.
  • Kathryn O’Donnell of UT-Southwestern
  • Maralice Conacci Sorrell of UT-Southwestern
  • Neeraj Saini of UT-MD Anderson Cancer Center
  • Neil Thapar of Barricade Therapeutics Corp.
  • Nina Keshavarzi of Celine Biotechnologies
  • Raphael G. Ognar & Henri Bayle of NKILT Therapeutics Inc.
  • Richard Austin & Michael Abrahamson of Reglagene Inc.
  • Tim Peterson & Joppe Nieuwenhuis of Bioio Inc.
  • Todd Aguilera & Eslam Elghonaimy of UT-Southwestern
  • Venkata Lokesh Battula of Siddhi Therapeutics Inc. at UT-MD Anderson Cancer Center
  • Weei-Chin Lin & Fang-Tsyr Lin of Baylor College of Medicine
  • Yong Li & Dongxiao Feng of Sotla Therapeutics at Baylor College of Medicine
  • Anil Sood & Zhiqiang An of UT-MD Anderson Cancer Center
  • Narendra Kumar & Jayshree Mishra of Texas A&M-College Station
  • Tao Wang of NightStar Biotechnologies Inc. at UT-Southwestern
  • Jian Hu of UT-MD Anderson Cancer Center
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Meet the esteemed judges for the 2026 Houston Innovation Awards

Meet The Judges

Editor's note: Judging is now underway for the 2026 Houston Innovation Awards, and it's time to meet the decision makers.

Our 2026 judging panel comprises past award winners who represent a variety of industries and areas of expertise. They are joined by InnovationMap's interim editor. All are deeply engaged in the Houston innovation ecosystem.

Our judging panel will review all nominee applications submitted across 10 prestigious categories. They will determine the 2026 finalists in all categories, and they will select the winners in all but one category — our people's choice award for Startup of the Year.

The sixth annual Houston Innovation Awards program will be presented in an all-digital format in 2026. We will announce this year's finalists and feature their stories throughout our special editorial series this fall. Then, stay tuned as we reveal the 2026 Houston Innovation Awards winners on InnovationMap.com in mid-November.

Sagar Dalal, Fervo Energy, 2025 Scaleup of the Year

Sagar Dalal

Sagar Dalal serves as chief of staff at Fervo Energy, a company pioneering the commercialization of next-generation geothermal power. In this role, he helps translate the CEO’s vision and priorities into execution, leading cross-functional strategic initiatives that support the company’s growth and operations.

Dalal brings nearly eight years of experience in structural engineering and project management from his time at Thornton Tomasetti and Tesla, where he engineered and built a wide range of infrastructure projects ranging from stadiums to manufacturing facilities. He holds an MBA from Stanford University and an MS in Civil Engineering from Texas A&M University. He is also a licensed professional engineer.

Aaron Fitzgerald, Mars Materials, 2025 Minority-founded Business of the Year

Aaron Fitzgerald

Aaron Fitzgerald is a three-time founder and carbon removal entrepreneur focused on reimagining how we make things. As the CEO of Mars Materials, he leads a team working to commercialize technologies that sequester captured carbon into industrial supply chains.

His vision for a defossilized future is shaped by a unique path through both policy, including a tenure in the United States Senate, and deep carbontech, with fellowships at The Lewis Latimer program, Breakthrough Energy, Prime Coalition, and Carbon 180.

Tatiana Fofanova, Koda Health, 2025 Health Tech Business of the Year

Tatiana Fofonova

Tatiana Fofanova, PhD, is the co-founder and CEO of Koda Health, an AI-enhanced patient decision support platform designed to make advance care planning (ACP) scalable, accessible, and patient-centered for patients with serious illness.

After earning her PhD in Translational Medicine at Baylor College of Medicine, she joined Texas Medical Center (TMC) as a Founder-in-Residence. It was there that she and her co-founders identified one of the most overlooked yet critical gaps in healthcare: the lack of meaningful, accessible advance care planning. Under her leadership, Koda Health now supports over 1 million patients through partnerships with organizations like Cigna, Privia, and Houston Methodist.

Lawson Gow, Greentown Labs, 2025 Incubator/Accelerator of the Year

Lawson Gow currently serves as chief strategy officer for Greentown Labs, which was named Incubator/Accelerator of the Year in the 2025 Houston Innovation Awards. Prior to joining Greentown Labs as Head of Houston in 2025, Gow was as a managing partner at Helium Capital, an investment and advisory firm that aims to support founders across the entire lifecycle of entrepreneurship.

He is also the founder of The Cannon, an innovation-infrastructure provider that operates a growing network of innovation hubs for its community of startups, entrepreneurs, investors, and corporate innovators.

Sarah Hein, March Biosciences, 2025 Female-founded Business of the Year

Sarah Hein

Sarah Hein is the founding CEO of March Biosciences, a clinical-stage cell-therapy company targeting challenging malignancies. Prior to cofounding March Biosciences, she was the founding Entrepreneur in Residence for the Texas Medical Center Innovation Accelerator for Cancer Therapeutics (TMCi ACT).

Formerly, she was a cofounder and the vice president of operations at Courier Therapeutics, a cancer immunotherapy startup acquired by Valo Health. She was also director of research at Resonant Therapeutics, an antibody therapeutics platform technology company. She began at Mercury Fund as a Venture Fellow directly after graduating with her PhD in Molecular Biology from Baylor College of Medicine.

Tanu Jain, FlowCare, 2025 Startup of the Year

Tanu Jain

Tanu Jain is a product executive, entrepreneur, founder and CEO of FlowCare, and registered nurse with a track record of building products from zero to global scale. She previously led product at BioIQ before founding FlowCare, a Houston-based period care infrastructure platform making period care a standard in every restroom. In under 16 months, FlowCare has signed deployed across four enterprise customers and impacted more than 1.5 million women.

FlowCare was named Startup of the Year at the 2025 Houston Innovation Awards, and Jain has been recognized with additional honors including the SDG Super Changemaker – Pewter — at the Global Sustainability Awards 2026.

Prabhdeep "Prab" Sekhon, Eclipse Energy, 2025 Energy Transition Business of the Year

Prabhdeep Singh Sekhon

Prabhdeep Singh Sekhon is CEO of Eclipse Energy, an energy technology company transforming depleted oil fields into low-cost, sustainable hydrogen resources through subsurface biotechnology. He brings nearly two decades of global energy experience spanning climate technology, venture capital, private equity, and multi-billion-dollar energy projects across five continents.

Previously, he held leadership roles at NextEra Energy Resources and Hess Corporation. He is also a founder and managing director of GreenLite Resources and a founding member of Cotogna Sports Group. He holds an MBA from Wharton, a Masters in Engineering from Texas A&M, and a BS from the University of Calgary.

Wade Pinder, Product Houston, 2025 Trailblazer Award Winner

Wade Pinder thinks of himself as an "ecosystem wayseeker," helping founders and builders in and around Houston find their footing, understand the landscape, and move through uncertainty with more clarity. Through Product Houston, he works at the intersection of product strategy, founder support, ecosystem mapping, and community-building, with a particular focus on helping people show up in the right rooms before they feel fully ready.

His background includes years in product management at Blinds.com and Home Depot, along with founding and leading the Houston Product Community for six years. He was recognized by as Mentor of the Year in the 2023 Houston Innovation Awards and received the Trailblazer Award in 2025.

Laura Furr Mericas, Interim Editor, InnovationMap

Laura Furr Mericas is interim editor for InnovatonMap.com and EnergyCapitalHTX.com. She is a longtime contributor to both sites and has reported on Houston's innovation ecosystem for InnovationMap since 2020. Previously, she served as web editor and data reporter for Houston Business Journal.

Report: Income for top 1 percent earners in Texas has surged in 2026

money matters

In a state where local billionaires are wealthier than they've ever been, high-earning Texans need to make $73,000 more than they did a year ago if they want to be among the top 1 percent of earners, a new report has revealed.

SmartAsset's study analyzed income thresholds for the top 1, 5, and 10 percent of earners in all 50 states and the District of Columbia, using 2022 IRS data for individual tax return filers (the most recent year available), adjusted to 2026 dollars.

Texas has the 11th highest income threshold, with residents needing to make a minimum of $817,158 to be considered among the top 1 percent of earners statewide. In 2025, Texans needed to make about $744,000 to be among the top 1 percent.

For comparison, residents living in the nation's capital must make at least $1.16 million to qualify as top 1 percent earners. The District of Columbia led the nation with the highest income threshold to be a top earner.

To be considered among the top 5 percent of earners in Texas, a resident would need to make $312,671. The income threshold to be considered among the top 10 percent is $210,609.

SmartAsset additionally found that 128,130 Texas residents qualified as top 1 percent earners in 2022. Nationally, the report estimated that fewer than 2 million households earn enough to be considered among the top 1 percent of earners nationwide, but 23 million households rank among the top 10 percent.

"In some places, households can enter the top 1 percent at income levels that fall well below the threshold elsewhere, reflecting an uneven landscape of wages and wealth," the report said.

A separate SmartAsset study that tracked the upper and lower thresholds for middle class households found Houston residents need to make anywhere from $42,907 to $128,722 to maintain their middle class status.

The top 10 states with the highest thresholds to be considered in the top 1 percent of earners in the U.S. are:

  • No. 1 – District of Columbia ($1,156,664)
  • No. 2 – Connecticut ($1,147,898)
  • No. 3 – Massachusetts ($1,006,921)
  • No. 4 – California ($987,325)
  • No. 5– New Jersey ($969,976)
  • No. 6 – New York ($959,562)
  • No. 7 – Florida ($956,449)
  • No. 8 – Washington ($903,303)
  • No. 9 – Colorado ($828,772)
  • No. 10 – Wyoming ($819,014)
---

This article originally appeared on CultureMap.com.

Here’s where wages grew the most in Houston since 2021, according to new report

pay raise

Bolstered by a thriving manufacturing sector, Waller County—the country’s second-fastest-growing county—leads all Houston-area counties for the growth of pay from 2021 to 2026, according to a new study.

The study, conducted by personal finance website SmartAsset, found average pay in Waller County rose 48 percent from 2021 to 2026. The county’s average weekly pay climbed from $891 to $1,323 during that period.

Manufacturing ranks as the No. 1 employment sector in Waller County, accounting for about 4,500 workers, according to Executive Pulse. Those workers earn an average pay of $77,442 per year.

Waller County powers up its manufacturing hub

Waller County’s manufacturing economy keeps expanding, almost certainly contributing to the 48 percent spike in average pay from 2021 to 2026.

Grundfos, the world’s largest producer of water pumps, broke ground in June on a manufacturing plant at its Brookshire campus. The Danish company’s U.S. headquarters is in Brookshire. In conjunction with the groundbreaking, Grundfos opened the Grundfos Academy Americas training center.

The new 143,000-square-foot facility will make pump systems and water technology, primarily for water utilities and commercial real estate landlords.

Grundfos expects construction to be completed by Q3 2027, with the first production lines planned to start in Q4 of next year.

“Our growing presence in Brookshire reflects both our confidence in the U.S. market and our long‑term commitment to investing where our customers and partners need us most,” Grundfos CEO Poul Due Jensen said in a release.

Another manufacturer, TMEIC Corporation America, recently opened its third U.S. plant at Twinwood Business Park in Brookshire. The 280,000-square-foot facility, which eventually might employ 500 people, makes uninterruptible power supply units and medium-voltage power drives. The $65 million plant includes a customer training center and tech development labs.

The Twinwood facility is the largest of TMEIC’s 13 factories around the world.

TMEIC’s two other U.S. manufacturing plants are in the Houston area. The company’s North American headquarters is in the Houston Energy Corridor.

Perhaps the biggest recent manufacturing prize for Waller County: Austin-based electric vehicle maker Tesla’s new 1.65 million-square-foot factory at Brookshire’s Empire West Industrial Park. The $200 million plant, expected to employ up to 1,500 people by 2028, produces utility-scale batteries for energy storage.

Other major manufacturers in Waller County include Daikin North America and Igloo.

Pay growth around the region

Here’s a rundown of 2021-26 pay growth in the Houston metro’s eight other counties, according to SmartAsset.

  • Austin County — 42 percent
  • Chambers County — 37 percent
  • Harris County — 33 percent
  • Liberty County — 31 percent
  • Montgomery County — 29 percent
  • Fort Bend County — 28 percent
  • Galveston County — 26 percent
  • Brazoria County — 23 percent

Statewide, Dickens County, outside of Lubbock, saw the most significant growth in wages. According to the study, wages grew by 212 percent over the five years, from $707 per week in 2021 to $2,204 per week in 2026.

Among all Texas counties, Waller was ranked No. 44 on the report.

Small counties in the High Plains and West Texas regions saw the largest percent changes in average weekly wage, according to the report. See the full findings here.

View All Listings